The Impact of Immunisation Programmes on Infectious Diseases in Spain

By Staff Writer

August 7, 2024

Introduction

Infectious diseases continue to challenge healthcare systems globally. However, effective immunisation strategies and national immunisation programmes (NIP) have proven to be efficient in controlling them. According to the Institute for Health Metrics and Evaluation (IHME), the global burden of infectious diseases decreased significantly from 1990 to 2019. This article will explore the impact of immunisation programmes in Spain, focusing on the burden of selected immunisation-preventable infectious diseases.

The Role of National Immunisation Programmes

National immunisation programmes play a crucial role in reducing the burden of infectious diseases. The European Centre for Disease Prevention and Control (ECDC) initiated the Burden of Communicable Diseases in Europe (BCoDE) project in 2006. This project developed a methodology to assess the impact of infectious diseases on population health in European Union/European Economic Area (EU/EEA) countries. The BCoDE methodology uses Disability-Adjusted Life Years (DALYs) to express the disease burden of an infectious disease. DALYs reflect both the impact on life expectancy and quality of life.

Current Burden of Disease in Spain

Despite immunisation efforts, the burden of certain immunisation-preventable infections remains high in Spain. Respiratory infections, such as influenza, invasive pneumococcal disease, and respiratory syncytial virus (RSV), exhibit the highest burden. Influenza alone accounts for 110.00 annual DALYs per 100,000 population. The burden of invasive pneumococcal disease and RSV follows with 25.20 and 10.57 annual DALYs per 100,000 population, respectively.

In Spanish older adults aged 60 or above, influenza imposes the greatest burden. This is potentially due to a low vaccination coverage rate (VCR), which reached only about 53.5% of those over 64 in the 2019–2020 vaccination campaign. Although this rate is high compared to other European countries, it falls short of the EU goal of 75%.

Figure 1. Burden of selected infectious diseases represented as annual DALYs per 100,000 population. The bars depict the median annual years lived with
disability (YLD) and years of life lost (YLL) per 100,000 population for each infection in Spain

Impact of High Vaccination Coverage Rates

Infections with high VCRs, such as hepatitis B virus (HBV), Haemophilus influenzae, meningococcus, measles, mumps, and varicella, result in a substantially lower disease burden. This highlights the importance of effective public health measures. Maintaining high VCRs can reduce the incidence of some infections to a minimum, as seen with poliomyelitis, rubella, diphtheria, and tetanus in Spain.

Figure 2. Annual burden of selected infectious diseases stratified by sex and age groups. The bars represent the total DALYs per 100,000 population/year for
all the infections evaluated.

Future Directions and Recommendations

The introduction of novel and more effective immunisation strategies could further reduce the burden of high-burden diseases. For instance, the Spanish Society of Geriatrics and Gerontology recommends universal vaccination for all adults ≥ 60 years of age with the high-dose (HD) influenza vaccine. The Spanish Ministry of Health also recommends vaccination for individuals ≥ 65 years, with some regions lowering the threshold to 60 years.

For RSV, the Spanish Association of Paediatrics recommends immunisation of neonates and infants under 6 months at the beginning of their first RSV season, as well as pregnant women. The only efficient preventive strategy in Spain at the time of this study was the single-dose monoclonal antibody nirsevimab.

Conclusion

The results of this analysis highlight a persisting high burden of respiratory infections despite the availability of effective vaccines and immunisation recommendations. Increasing VCRs and introducing novel immunisation strategies could further reduce this burden. Maintaining high VCRs for low-burden diseases is essential to prevent outbreaks and keep these diseases under control. These estimates provide a basis to guide prevention strategies, prioritise interventions, and make public health decisions in Spain.

Reference url

Recent Posts

biosimilars price competition
      

The Impact of MFN Pricing on the U.S. Biosimilar Market

💊 Could MFN Pricing Undermine Biosimilars?

MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.

Explore the risks and what stakeholders can do to protect market sustainability.

#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess

EU AI Act Healthcare Compliance
     

Navigating EU AI Act Healthcare Compliance: Proactive Steps for Ethical AI Integration

🔍 Are you prepared for the upcoming EU AI Act in healthcare?

As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.

Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

hepatitis vaccine uptake
         

Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists

💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?

A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.

Join the conversation on enhancing vaccination strategies for better health outcomes!

#SyenzaNews #Healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.